News
The Position of Lurasidone in Schizophrenia Therapy − Current Conclusions and Consensus of the Expert Panel
Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA) indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. The efficacy of lurasidone has been confirmed by a number of clinical studies, compared to placebo and using active control with known antipsychotics (e.g., olanzapine or quetiapine). The aim of the recently published study was to define current possibilities of using lurasidone in the treatment of schizophrenia and to identify patient groups that would…
Recommendations for Nutrition of Patients at Risk of or with Pressure Ulcers
Nutrition plays a crucial role in the prevention and treatment of pressure ulcers. In 2019,…
Classification and Management of Chronic Wounds
Chronic wounds are common comorbidities that increase the morbidity and mortality of patients.…
Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall…
Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Type 2 diabetes mellitus (DM2) is a serious chronic metabolic disease whose prevalence has been…
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is…
Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The…
Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis
Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on…
Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had…
Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension
Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor,…
Popular this week
- HPV-Related Cervical and Oropharyngeal Cancers: Why They Differ – and What It Means for Clinical Practice
- MUDr. Marek Štefan: Cooperation With Pharmacists Is Essential in Antibiotic Therapy
- What Is the Potential of a Monovalent Antibody in Anti-NMDA Receptor Encephalitis?
- New Imaging Probe Lights Up Brain Tumors
- BENIGN DERMATOSIS OF PENIS